Serda Rita E, Godin Biana, Blanco Elvin, Chiappini Ciro, Ferrari Mauro
University of Texas Health Science Center, Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030, USA.
Biochim Biophys Acta. 2011 Mar;1810(3):317-29. doi: 10.1016/j.bbagen.2010.05.004. Epub 2010 May 21.
The daunting task for drug molecules to reach pathological lesions has fueled rapid advances in Nanomedicine. The progressive evolution of nanovectors has led to the development of multi-stage delivery systems aimed at overcoming the numerous obstacles encountered by nanovectors on their journey to the target site.
This review summarizes major findings with respect to silicon-based drug delivery vectors for cancer therapeutics and imaging. Based on rational design, well-established silicon technologies have been adapted for the fabrication of nanovectors with specific shapes, sizes, and porosities. These vectors are part of a multi-stage delivery system that contains multiple nano-components, each designed to achieve a specific task with the common goal of site-directed delivery of therapeutics.
Quasi-hemispherical and discoidal silicon microparticles are superior to spherical particles with respect to margination in the blood, with particles of different shapes and sizes having unique distributions in vivo. Cellular adhesion and internalization of silicon microparticles is influenced by microparticle shape and surface charge, with the latter dictating binding of serum opsonins. Based on in vitro cell studies, the internalization of porous silicon microparticles by endothelial cells and macrophages is compatible with cellular morphology, intracellular trafficking, mitosis, cell cycle progression, cytokine release, and cell viability. In vivo studies support superior therapeutic efficacy of liposomal encapsulated siRNA when delivered in multi-stage systems compared to free nanoparticles. This article is part of a Special Issue entitled Nanotechnologies - Emerging Applications in Biomedicine.
药物分子抵达病理损伤部位这一艰巨任务推动了纳米医学的快速发展。纳米载体的不断演进促使了多阶段递送系统的开发,旨在克服纳米载体在前往靶位点途中遇到的众多障碍。
本综述总结了关于用于癌症治疗和成像的硅基药物递送载体的主要研究结果。基于合理设计,成熟的硅技术已被用于制造具有特定形状、尺寸和孔隙率的纳米载体。这些载体是多阶段递送系统的一部分,该系统包含多个纳米组件,每个组件都设计用于完成特定任务,共同目标是实现治疗药物的定点递送。
在血液中边缘化方面,准半球形和盘状硅微粒优于球形微粒,不同形状和尺寸的微粒在体内具有独特的分布。硅微粒的细胞黏附和内化受微粒形状和表面电荷影响,后者决定血清调理素的结合。基于体外细胞研究,内皮细胞和巨噬细胞对多孔硅微粒的内化与细胞形态、细胞内运输、有丝分裂、细胞周期进程、细胞因子释放和细胞活力相容。体内研究支持与游离纳米颗粒相比,脂质体包裹的小干扰RNA在多阶段系统中递送时具有更高的治疗效果。本文是名为“纳米技术——生物医学中的新兴应用”的特刊的一部分。